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Tobacco use is the single most preventable cause of disease, 
disability, and death in the United States with an estimated 
443,000 premature deaths each year, and another 8.6 million 
people live with serious illness caused by smoking. (CDC. 
Tobacco Use-Targeting the Nation’s Leading Killer, 2011).
In 1984, Attorney General C. Everett Koop presented the 
first of a series of reports revealing the health consequences 
of tobacco use including involuntary exposure. While the 
United States has not overcome the challenges of the “smoke-
free” society that Koop hoped for by the year 2000, industries 
across the country now recognize the importance of testing.
For over 20 years a wide range of tobacco (cotinine) test-
ing products for multiple specimen types has been available. 
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Abstract
Today, smoking today is one of the most common bad habits in the world. Smoking, both active and passive, increases perinatal mortality by 27%, 
increases the incidence of heart attack and detachment of the placenta, reduces the body weight of the baby, changes the development of coronary artery 
disease in the newborn, and increases the frequency of spontaneous abortions and stillbirths. Therefore, laboratory studies of nicotine and its catabolic 
product, cotinine, is an important indicator for monitoring pregnancy.
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Котинин – биомаркёр курения табака во время беременности
Курение в современном мире является одной из наиболее распространённых вредных привычек. Курение, как активное, так и пассивное, 
увеличивает перинатальную смертность на 27%, повышает частоту инфаркта и отслойки плаценты, снижает массу тела новорожденного, из-
меняет развитие коронарных артерий у новорожденного, увеличивает частоту самопроизвольных абортов и мертворождений. Поэтому, лабора-
торное исследование содержания никотина и продукта его катаболизма, котинина, является важным показателем мониторинга беременности.
Ключевые слова: беременность, котинин, курение, новорожденные.
Cotinine is the first-stage metabolite of nicotine. Because the 
window of detection for nicotine is relatively short (approxi-
mately 2 hours), cotinine extends the window of detection 
for several days and is the preferred method of screening for 
tobacco use [1].
Levels of cotinine in urine tests are typically much higher 
than in serum or oral fluid as a result of the higher concentra-
tions of cotinine found in urine [2, 3, 4].
A rapid, one step test for the qualitative detection of Coti-
nine (nicotine metabolite) in human urine (for determination 
of Smoking Status Only). The COT One Step Cotinine Test 
Device (Urine) is a lateral flow chromatographic immunoas-
say for the detection of Cotinine in human urine at a cut-off 
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concentration of 200ng/mL. The test device contains mouse 
monoclonal antibody-coupled particles and Cotinine-protein 
conjugate. The COT One Step Cotinine Test Device (Urine) 
provides only a qualitative, preliminary analytical result.
A secondary analytical method must be used to obtain a 
confirmed result. Gas chromatography/mass spectrometry 
(GC/MS) is the preferred confirmatory method [5] (tab. 1).
Table 1
OraSure Test Cutoffs
Biologic fluid Urine Blood serum Oral fluid
Types of Exposure 500 ng/mL 25 ng/mL 10 ng/mL
Second-Hand Smoke < 100 ng/mL < 15 ng/mL < 3 ng/mL
Light Smoking 100-500 ng/mL 15-100 ng/mL 3-33 ng/mL
Regular Smoking > 500 ng/mL > 100 ng/mL > 33 ng/mL
A number of contributing factors influence cotinine 
testing outcomes such as:
• size of the individual;
• percentage of body fat present;
• rate of metabolism;
• hydration state of the individual;
• type of cigarette/cigar/pipe smoked or tobacco chewed;
• smoking style;
• elapsed time from smoking to testing;
• the pH of the urine (if urine testing is conducted).
The adverse effect of prenatal smoking exposure on human 
fetal development and growth has been a major public health 
issue. Active or passive smoking during pregnancy can result 
in a wide variety of adverse outcomes, including intrauterine 
growth retardation, premature birth, stillbirth, sudden infant 
death syndrome, respiratory diseases, and otitis media. Smo-
king in pregnancy has also been associated with an increased 
risk of attention deficit disorder and other learning disorders 
in childhood. Oxidative stress in pregnant women who smoke 
is assumed to be increased by oxidants and free radicals in to-
bacco smoke. In pregnancies complicated by cigarette smoking 
prooxidant-antioxidant imbalance may have a pathomorpho-
logical and pathophysiological effect in the fetus.
Maternal smoking during pregnancy greatly increases 
the rate of perinatal morbidity/mortality and is the major 
risk factor for Sudden Infant Death Syndrome. Slotkin T. et 
al. studies in developing rodents indicate that nicotine is a 
neuronteratogen that targets monoamine pathways involved 
in the responses to hypoxia [6].
Smoking and severe asthma exacerbations in pregnancy 
are risk factors for low birth weight babies. During pregnancy, 
asthma exacerbations are more common and more severe in 
current smokers than in women nonsmokers. The risk of ef-
fects of maternal asthma on the fetus may be greater among 
smokers [7].
Maternal smoking during pregnancy is known to be as-
sociated with not only intrauterine fetal growth retardation 
and low birth weight, but also with disturbances in postnatal 
growth and development. Nicotine and its major metabolite 
cotinine can cross the placental barrier.
The data on smoking which had been obtained from a 
direct personal interview were verified by determination of se-
rum cotinine concentration. So, more objective investigations 
of maternal smoking are methods that determine levels of co-
tinine in the biological liquids of mothers and their newborns.
The findings obtained by Karmowski A. et al. submit new 
cognitive values to the diagnosis of pathology of pregnancy, 
i.e. the influence of nicotine on the bodies of mothers and 
new-born children, estimated by the assay of cotinine, the 
most important metabolite of nicotine. The authors lay a 
particular stress on the “colostrum-milk way” in the mother-
child relationship [8].
The findings presented by Dobek D. and coauthors (1998) 
contribute to the diagnosis of pathology of pregnancy, i.e. they 
assess the influence of nicotine on the bodies of mothers and 
new-born children, estimated by concentration of cotinine. 
The mean proportional share of cotinine in the fluids and 
organs in the pregnant women smoking actively was as fol-
lows: urine 72.1%, amniotic fluids 14.3%, colostrum 8.9% 
and placenta 4.7%. The authors pay particular attention to 
the “colostrum-milk way” in the mother-child relationship.
Women who smoke and breast-feed pose an unknown 
threat to their infants’ health. Stepans M. and Wilkerson N. 
investigated relationships between ingestion of nicotine in 
breast milk and physiological effects in the infant. The physi-
ological effects measured in infants were temperature, pulse, 
respiration, systolic blood pressure, and oxygen saturation. 
Five smoking and five nonsmoking mother-infant pairs were 
studied. Breast milk was analyzed for nicotine using gas chro-
matography. Breast milk from smoking mothers contained a 
mean of 33.1 ng/mL of nicotine while the breast milk from 
nonsmoking mothers contained a mean of less than 6.45 
ng/mL of nicotine. The physiological measurements of the 
infants were taken before and 20 min after breast-feeding. 
After breast-feeding, the infants of smoking mothers had a 
significant change in respiration and oxygen saturation while 
infants of nonsmoking mothers had a significant change in 
pulse only. Their results provide a scientific basis for counsel-
ing smoking mothers who choose to breast-feed [9].
For the past 40 years, evidence has been accumulating on 
the effects of passive smoking on the fetus and on children. 
Over this period, research methods have become more precise 
and accurate, with confounding factors controlled for and 
actual exposure to smoke measured and validated by cotinine 
tests of body fluids. Nearly 200 research papers published 
worldwide were reviewed by Charlton A. [10]. It is difficult to 
separate prenatal and postnatal effects with regard to growth, 
development, and lung function retardation. There is now suf-
ficient evidence that health problems in children are related 
to maternal and to a lesser degree paternal, smoking during 
pregnancy, and, after birth, to exposure to environmental 
tobacco smoke in the home and daycare centers. Exposure 
to environmental tobacco smoke (ETS) should be noted on 
pediatric patients’ problem lists and addressed at each visit.
The effects of smoke exposure via mothers’ milk and/or 
via passive smoking during the first year of life were investi-
gated by Schulte-Hobein B. et al. in a prospective longitudinal 
matched-pair study. In order to evaluate the extent of smoke 
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exposure, cotinine was measured in children’s urine and in 
breast milk once a month throughout the first year of life. 
Cotinine in the urine was significantly dependent on feeding 
behaviour: Infants who were breast fed showed concentrations 
10-fold higher than those who were bottle fed. Cotinine excre-
tion in the urine of infants from smoking mothers, who were 
not breast fed (nicotine exposure via only passive smoking) 
was even higher than that of adult passive smokers. If infants 
from smoking mothers were breast fed, their urinary cotinine 
excretion was in the range of adult smokers [11].
In Canada, 8% to 20% of infants are breast-fed by mothers 
who smoke. To determine whether breast-feeding increases 
infants’ exposure to tobacco smoke byproducts, urinary coti-
nine excretion was measured by Labrecque M. et al. (1989) in 
172 babies, 33 of whom were breast-fed. A milk sample was 
taken from the mothers who were breast-feeding, and coti-
nine was measured with gas chromatography. The breast-fed 
babies had a median cotinine to creatinine ratio of 433 ng/mg, 
whereas the bottle-fed babies’ median was 200 ng/mg. The 
correlation coefficient between the number of cigarettes 
smoked by the mother and the breast milk cotinine concen-
tration was significant. Moreover, urine cotinine values from 
the breast-fed babies increased with higher concentrations of 
cotinine in the mother’s milk.
The extent of smoke exposure via mother’s milk and 
passive smoking was investigated by Schwartz-Bicken-
bach D. (1987) in a prospective, longitudinal matched-pair 
study by comparison between children, whose mothers 
smoked substantially throughout pregnancy and nursing 
period and children whose mothers did not smoke. The 
preliminary results show that not only infants of smoking 
mothers but also those of smoking fathers show a reduction 
in birth weight. Smoking mothers weaned their babies earlier 
than non-smokers. Cotinine concentrations in breast milk 
depended on the number of cigarettes smoked. The highest 
urinary excretion of cotinine (as expressed by ng cotinine/mg 
creatinine ratios), were observed in infants fully breast-fed by 
smoking mothers. Thus it is demonstrated that both nursing 
and (to a lower degree) passive smoking contribute to the 
exposure of infants to nicotine and its metabolite cotinine.
An analysis of 44 milk samples from 23 nursing smokers 
performed by Luck W. and Nau H.(1984) revealed that there 
was a linear correlation between nicotine concentrations in 
serum and in milk. The nicotine concentrations in milk were 
considerably higher than the corresponding serum concen-
trations. There was also a linear correlation between the 
cotinine concentrations in serum and in milk. The cotinine 
concentrations in milk were lower than the corresponding 
serum concentrations. The half-life of nicotine in milk was 
determined in four additional smoking mothers. The half-life 
of nicotine in milk, T50 = 97 ± 20 min, slightly exceeded the 
half-life of nicotine in serum T50 = 81 ± 9 min; the difference 
between these two values was not statistically significant. 
Cotinine concentrations remained fairly consistent during a 
4 hour interval without smoking.
The exposure of infants to nicotine via the breast milk of 
smoking mothers or via inhaled side-stream smoke (“passive 
smoking”) was evaluated by Luck W. and Nau H. (1985). New-
born infants nursed by smoking mothers and unexposed to 
passive smoking showed measurable serum concentrations of 
nicotine (0.2 to 1.6 ng/mL) and its main metabolite, cotinine 
(5 to 30 ng/mL), and also excreted measurable amounts of 
nicotine and cotinine in their urine: the ratio of nanograms 
of nicotine/milligrams of creatinine (N/C ratio) ranged from 
5.0 to 110, and the corresponding ratio of nanograms of co-
tinine/milligrams of creatinine (C/C ratio) from 10 to 555. 
The significant serum concentrations and urinary excretion 
rates of nicotine in the breast-fed infants of smoking mothers 
suggest that nursing contributes to the nicotine exposure of 
these neonates. In older infants, the wide variation of cotinine 
excretion values did not allow for separate evaluation of the 
two exposure routes.
Also, the relationship between nicotine and cotinine con-
centrations in mother’s milk (including 24 h profiles) and the 
number of cigarettes consumed was studied by Luck W. and 
Nau H. [12]. A total of 206 milk samples were collected from 
34 nursing, smoking mothers. The mothers were distributed 
into three groups: Group I (1-10 cigarettes/day), group II (11-
20 cigarettes/day) and group III (21-40 cigarettes/day). Milk 
samples from all nursing periods in a 24 h interval were col-
lected. Nicotine and cotinine concentrations were measured 
by specific gas chromatographic techniques. Over a time 
interval of 24 h, the nicotine concentrations varied greatly in 
the milk of smoking mothers, while the cotinine concentra-
tions remained relatively constant. Their results indicate that 
the exposure of the nursed infant to nicotine and cotinine via 
milk depends on the daily cigarette consumption but also on 
individual smoking habits; the time of smoking and smoking 
frequency prior to nursing, and the time interval between 
nursing and the last cigarette.
A close correlation was found by Dahlström A. et al. (1990) 
between nicotine concentrations in the mothers’ plasma and 
milk after smoking, the milk/plasma ratio being 2.9. The 
amount of nicotine transferred to the infant increased from 
0.09 to 1.03 micrograms/kg of the infant body weight when 
mothers smoked before breast-feeding. The daily dose of 
nicotine via the mothers’ milk was 6 micrograms per kg of the 
infant body weight. Cotinine, but not nicotine, concentrations 
in the plasma and milk of the mothers and the urine of the 
infants reflected the smoking habits of the mothers during 
pregnancy. There was no correlation between nicotine and 
cotinine concentrations in the infant’s urine and the amount 
of nicotine given to the infant via the mother’s milk.
During Dahlström A.’s study (2004), home visits were 
conducted, parental smoking habits were recorded, and the 
times of mothers’ last smoke or taking of snuff and breastfeed-
ing were recorded. Breast milk and infant urine samples were 
collected. Concentrations of nicotine and cotinine were anal-
ysed with gas chromatography. The amount of milk ingested 
during the home visit was calculated by weighing the infants. 
The concentrations of the metabolite cotinine in infant urine 
correlated with the dose of nicotine ingested during the home 
visit. Breastfed infants with a smoking or snuff-taking mother 
are exposed to nicotine in breast milk.
During home visits, the infant’s urine and mothers’ milk 
were sampled and concentrations of nicotine and cotinine 
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were analyzed by Dahlström A. et al. [13]. The smoking moth-
ers exposed their infants to nicotine in milk with a median 
nicotine concentration of 47 mcg/L. Analysis of the infants’ 
urine showed that the nonsmoking group had 0.8 and the 
smoke group 60 mcg cotinine/L. The frequency domain low-
to-high frequency (LF/HF) ratio was correlated to milk nico-
tine concentrations in the milk sample, from smoking mothers.
Serial milk samples were collected by Ilett K.F. (2003) 
from the women over sequential 24-hour periods when they 
were smoking and when they were stabilized on the 21-mg/d, 
14-mg/d, and 7-mg/d nicotine patches. Nicotine and cotinine 
in milk were quantified by high-performance liquid chro-
matographic (HPLC), and the infant dose was calculated. 
Plasma concentrations of nicotine in the breast-fed infants 
were assessed, and the infants were also clinically assessed. 
They concluded that the absolute infant dose of nicotine and 
its metabolite cotinine decreases by about 70% from when 
subjects were smoking or using the 21-mg patch to when they 
were using the 7-mg patch.
The relationship between tobacco smoking in pregnancy 
and breastfeeding is of public health importance. The Jedry-
chowski W. et al. birth cohort study provided the opportunity 
to investigate whether the negative relationship between pas-
sive smoking, measured by the cotinine concentrations in 
maternal blood at delivery and breastfeeding in postpartum, 
could also be confirmed in nonsmoking mothers [14].
While there are sufficient data regarding the negative 
effect of exposure to the constituents of tobacco smoke on 
newborn infants’ birth weights, it is still unclear whether 
this effect may originate in early pregnancy. Ultrasound 
biometric measurements of fetal bi-parietal diameter (BPD), 
abdominal circumference (AC) and femur length (FL) were 
performed by Hanke W. and colab. at the time of enrollment 
[15]. Serum cotinine concentration was determined at 20-24 
weeks of gestation by gas chromatography with mass spec-
trometry detector (GC/MS) to assess environmental tobacco 
smoke (ETS) exposure during the previous evening and the 
morning of the same day. ETS exposure (passive smoking) 
was assumed to occur when the level of serum cotinine 
ranged from 2-10 ng/mL. In a multiple regression model for 
bi-parietal diameter (BPD), after adjustment for pregnancy 
duration at the time of ultrasound examination, fetal gender, 
and maternal pre-pregnancy weight, a statistically significant 
negative association was found between the BPD and serum 
cotinine concentration. A similar association was identified 
for subjects with serum cotinine concentrations below 10 ng/
mL, corresponding to passive smoking [15].
Leonardi-Bee J. and colab.(2008) wrote that exposure of 
non-smoking pregnant women to ETS reduces mean birth 
weight by 33g or more, and increases the risk of birth weight 
below 2500g by 22%, but has no clear effect on gestation or 
the risk of being small for gestational age.
The retrospective study by Ward C. and colab. used inter-
view data from parents of 18,297 children born in 2000/2001 
and living in the UK 9 months afterwards (the Millennium 
Cohort Survey) [16]. Comparison of birth weight, sex and 
gestational age specific (SGA) z score, birth before 37 weeks 
and birth weight < 2.5Kg (LBW) in infants born to women 
exposed to: no tobacco smoke, ETS only and maternal smok-
ing whilst pregnant. In the UK, the prevalence of domestic 
ETS exposure and maternal smoking in pregnancy remains 
high, and ETS exposure lowers infants’ birth weights.
There is growing evidence that ETS exposure may nega-
tively affect birth outcomes, especially birth weight (Pogodina 
C., 2009). Educational anti-tobacco campaigns and quit smok-
ing initiatives should target both mothers and fathers to ensure 
smoke-free living conditions and a healthy environment for 
all family members.
Mennella J.A. (2007) wrote that although there was no 
significant difference in breast milk intake, despite the taste 
changes in the milk, infants spent significantly less time sleep-
ing during the hours immediately after their mothers smoked 
(53.4 minutes), compared with the session when their mothers 
abstained from smoking (84.5 minutes).
According to Letourneau A.R. data (2007), approximately 
40 percent of women smokers will stop smoking cigarettes 
during pregnancy; however, 70 percent of those who stop will 
resume smoking by 6 months postpartum. Interventions may 
be more effective if they include strategies aimed at increas-
ing breastfeeding rates and assisting household members to 
stop smoking.
The concentration measurements made Milnerowicz H. 
and Chmarek M. (2005) employed the following methods: 
total protein by Lowry, albumin by colorimetry, cotinine 
and lactoferrin by ELISA tests. The assessment of tobacco 
smoke exposure was based on concentrations of cotinine in 
breast milk: 197 ± 98 ng/ml in smokers and 23 ± 11 ng/mL 
in non-smokers; and in serum: 179 ± 87ng/mL and 32 ± 19 
ng/mL, respectively.
A high-performance liquid chromatographic (HPLC) as-
say was used by Page-Sharp M. et al. (2003) for the determina-
tion of nicotine and cotinine in human milk. It was developed 
using an extraction by liquid-liquid partition combined with 
back extraction into acid, and followed by reverse-phase 
chromatography with UV detection of analytes. The assay was 
linear up to 500 microg/L for both nicotine and cotinine. They 
found that this method was sensitive and reliable in measuring 
nicotine and cotinine concentrations in milk from a nursing 
mother who participated in a trial of the nicotine patch for 
smoking cessation.
Bramer S. L. and Kallungal B. A. (2003) wrote that subjects 
enrolled in studies are not always screened for routine habits 
such as smoking. Personal history is not always reliable and 
therefore an objective biomarker is necessary to screen for 
smokers. A serum cotinine concentration of 10 ng/mL should 
be employed as a breakpoint for non-smokers versus smokers; 
other non-invasive alternatives are collection of urine, saliva, 
or hair (with suggested breakpoints of 200 ng/mL, 5 ng/mL 
and 0.3 ng/mg, respectively); screening questions should be 
accompanied by testing for cotinine; and the inclusion of 
smokers in studies should be considered once the impact of 
smoking on the targeted population is understood.
Cotinine levels by radio-immuno-analysis (RIA) were 
evaluated by Berlanga Mdel R. (2002). Cotinine was 19 times 
greater in the smoking mothers and six times higher in their 
infants, as compared to the nonsmoking group.
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Also Berlanga Mdel R. (2002) wrote that hair nicotine 
levels were better able to discriminate the groups of children 
according to their household’s smoking habits at home than 
urine cotinine. Furthermore, hair nicotine levels were more 
strongly correlated with number of smokers in the house, 
and the number of cigarettes smoked by parents and other 
members of the child’s households. Hair nicotine was better 
related to the questionnaire variables of smoking in a multi-
variate regression model than urine cotinine.
Biomarkers can provide valid information on ETS expo-
sure, the preferred biomarker being cotinine. However, no 
reference range of hair cotinine exists to distinguish among 
active, passive, and unexposed nonsmokers. The Florescu 
A. and colab. study identifies cutoffs to validate cotinine as 
a marker for exposure to ETS [17]. Data were obtained from 
six databases (four in the U.S., one in Canada, and one in 
France). Active smoking and exposure to ETS were measured 
in the hair of women of reproductive age, pregnant women, 
their children, and neonates. Subjects were classified into 
active smokers, passively exposed to ETS, and unexposed 
nonsmokers. These new values should facilitate clinical 
diagnosis of active and passive exposure to tobacco smoke. 
Such diagnosis is critical in pregnancy and in a large number 
of tobacco-induced medical conditions.
Cotinine level was analyzed by Polańska K. et al. by means 
of gas chromatography with mass spectroscopy (GC-MS) [18]. 
They chose more than 15 ng/mL as serum cotinine level for 
smokers, 2-15 ng/mL for ETS exposure and less than 2 ng/mL 
for non-smokers not exposed to ETS. Among non-smoking 
and not ETS-exposed women, 17% had cotinine level indicat-
ing active smoking and 74% ETS exposure. About 4% of the 
women who indicated ETS exposure during pregnancy had 
serum cotinine level higher than 15 ng/mL indicating active 
smoking. The information about active and passive smoking 
during pregnancy obtained from mothers and based on the 
questionnaire does not indicate objective maternal exposure 
to tobacco smoke.
Since the publication of the U.S. Surgeon General Reports 
in 1996 and 2006 and the report of the California Environmen-
tal Protection Agency in 1999, many reports have appeared 
on the contribution of air and biomarkers to different facets 
of the secondhand smoke (SHS) issue, which are the targets 
of this review. The recent studies have allowed earlier epide-
miological surveys to be biologically validated, and have their 
plausibility demonstrated, quantifyingthe levels of exposure 
to SHS before the bans in various environments showed the 
deficiencies of mechanical control methods and of partial 
bans and leading to the frequently correct implementation 
of the efficient total bans. More stringent regulation remains 
necessary in the public domain (workplaces, hospitality 
venues, transport sector, etc.) in many countries. Personal 
voluntary protection efforts against SHS are also needed in 
the private domain (homes, private cars). The effects of SHS 
on the cardiovascular, respiratory and neuropsychic systems, 
on pregnancy and fertility, on cancers and on SHS genotoxic-
ity are confirmed through experimental human studies and 
through the relationship between markers and prevalence of 
disease or of markers of disease risk [19].
Cotinine can be measured in plasma, urine, or saliva, 
demonstrated by Etzel R.A. (1990). However, distinguishing 
between active and passive smoking on the basis of a cotinine 
measurement may be difficult. Passive smokers usually have 
cotinine concentrations in saliva below 5 ng/mL, but heavy 
passive exposure can result in levels greater than or equal to 
10 ng/mL. Levels between 10 and 100 ng/mL may result from 
infrequent active smoking or regular active smoking with low 
nicotine intake. Levels greater than 100 ng/mL are probably 
the result of regular active smoking. Four categorizations of 
tobacco smoke exposure are suggested on the basis of saliva 
cotinine concentrations.
Experience of nausea and vomiting during pregnancy was 
self-reported for each trimester. Adjustments were made by 
Boylan S.M. (2012) for confounders, including salivary coti-
nine as a biomarker of current smoking status. There were no 
significant associations between fetal growth restriction and 
nausea and vomiting in pregnancy, even after adjustment for 
smoking and alcohol intake.
The following study used the Korea National Health and 
Nutrition Examination Survey IV-2, 3 (2008-2009). A urinary 
cotinine test was administered to 5485 women of at least 19 
years of age. Individuals whose cotinine level was 50 ng/mL 
were categorized as smokers. A multiple logistic regression 
analysis was performed to estimate the extent to which body-
related variables affect female smoking [20].
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Introducere
Maladiile care apar din cauza modificărilor cardiovascu-
lare, constituie o preocupare de bază ale medicinii naţionale 
şi un obiectiv important al cercetărilor ştiinţifice. Hiperten-
siunea arterială este unul din factorii de risc în dezvoltarea 
patologiilor cardiovasculare, care ocupă unul din primele 
locuri în structura morbidităţii, invalidităţii şi mortalităţii. 
Conform datelor Ministerului Sănătăţii din Republica Mol-
dova, în anul 2011, în Republica Moldova au fost înregistrate 
891 de decese din cauza hipertensiunii arteriale la 100 mii de 
locuitori, comparativ cu 867 de decese la 100 mii locuitori 
în anul 2010. Diverse medicamente, aparţinând unor grupe 
farmacologice variate, sunt capabile să micşoreze presiunea 
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Antihypertensive properties of Benzituron
Benzituron or S-benzylisothiourea chloride is exposed to a new range of hypotensive substances, isothiourea derivatives, it is able to reduce and 
stabilize the level of the arterial pressure. The benzituron solution, in a dosage of 2 mg/kg, shows a noticeable decrease in hypotension and antihyperten-
sion that lasts 4-5 hours. Benzituron can manifest hypotensive action in arterial hypertension. This hypotension is caused by phenylefrine, with increased 
efficacy when taken with benzituron hypotension, which shows that alpha-adrenoreceptors are not occupied and can react with alpha-adrenomimetic 
drug. Ephedrine induced hypertension also is decreased by benyituron, even below the initial level. Also, repeated administration of ephedrine doesn’t 
influence vasodilating action of benzituron. Our research showed that one-time administration of angiotensine-II increased BP (blood pressure), while 
a subsequent injection of benzituron decreased it. Angiotensine-II, when administered 60 min after benzituron, reestablished the level of blood pressure. 
Key words: isothiourea derivative, benzituron, blood pressure, antihypertensive effect.
Антигипертензивные свойства бензитурона
Бензитурон или S-бензилизотиуроний хлорид, относится к новому классу гипотензивных средств, производных изотиомочевины, способ-
ных снизитъ и стабилизировать уровень артериального давления (АД). Раствор бензитурона в дозе 2 мг/кг вызывает выраженное и медленное 
гипотензивное и антигипeртензивное действия, на длительное время (4-5 часов). Бензитурон может снизить АД, при гипертонии вызванное 
фенилэфрином, а эффективность фенилэфрина при гипотонии вызванное бензитуроном показывает, что альфа - aдренорецепторы свободны 
и реагируют на администрацию альфа-адреномиметика. Гипертония вызванная эфедрином также понижается бензитуроном, ниже исходных 
данных, а повторное введение эфедрина не влияет на сосудораширяющее действие бензитурона. Однократное введение ангиотензина-II вы-
зывает значительное увеличение АД, а последующее инъекция бензитурона сопровождаеться снижением АД. Уровень АД восстанавливается 
после повторного введения ангиотензина-II на 60-й минуте действия бензитурона.
Ключевые слова: производные изотиомочевины, бензитурон, артериальное давление, антигипотензивное действие.
arterială şi sunt destul de active dar, deseori, provoacă reacţii 
adverse, ceea ce şi limitează utilizarea largă a lor. În acest con-
text, valorificarea unor surse noi de medicamente accesibile, 
eficace şi inofensive pentru organismul uman constituie o 
problemă destul de actuală.
Noii derivaţi izotioureici – izoturon, şi alchilizotioureici 
– difetur (raviten) sunt cunoscuţi ca vasoconstrictori efectivi 
în hipotensiunea arterială [1, 2], iar substanţa clorură-S-ben-
zilizotiuroniu (benzituron), a demonstrat în urma screening-
ului (fig.1) a 18 substanţe un efect vasodilatator cu reducerea 
esenţială a presiunii arteriale pentru timp îndelungat (4-5 ore).
Acest fapt a şi motivat studiul benzituronului, care ar avea 
avantajul de a optimiza şi extinde posibilităţile de reglare 
